Wilms Tumour

Gene: CTR9

Green List (high evidence)

CTR9 (CTR9 homolog, Paf1/RNA polymerase II complex component)
EnsemblGeneIds (GRCh38): ENSG00000198730
EnsemblGeneIds (GRCh37): ENSG00000198730
OMIM: 609366, Gene2Phenotype
CTR9 is in 6 panels

1 review

Chirag Patel (Genetic Health Queensland)

Green List (high evidence)

Evidence for gene-disease association for Wilms tumour. Truncating variants are a rare cause of familial Wilms tumour.

PMID: 25099282
Inactivating CTR9 mutations found in 3 of 35 Wilms tumour families, through exome and Sanger sequencing. All variants were absent in 1,000 population controls and segregated with Wilms tumour in the family with second mutational event present in available tumours. CTR9 is a key component of the polymerase-associated factor 1 complex which has multiple roles in RNA polymerase II regulation and is implicated in embryonic organogenesis and maintenance of embryonic stem cell pluripotency.

PMID: 39293508
2 female siblings with Wilms tumour (1 with bilateral Wilms tumour) and a pathogenic splice site variant in the CTR9 gene, leading to deletion of exon 9, and inherited from her asymptomatic father. The loss of heterozygosity in the tumour was confirmed.

PMID: 29292210
3 affected siblings from 1 family with Wilms tumour (one presenting an aggressive bilateral tumour). They identified a novel CTR9 germline variant, located in a consensus splice acceptor site, which was found to segregate with Wilms tumour in this family. The variant leads to the skipping of the entire exon 9 in the mRNA, which is predicted to encode a truncated CTR9 protein, strongly suggesting that it is pathogenic. They also detected loss of heterozygosity in the index case tumour, which is consistent with CTR9 being a tumour suppressor gene.
Sources: Expert list, Expert Review, Literature
Created: 26 Sep 2024, 1:28 a.m. | Last Modified: 26 Sep 2024, 1:35 a.m.
Panel Version: 0.30

Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted

Phenotypes
Wilms tumor, MONDO:0006058; Wilms tumor predisposition, no MIM#

Publications

Details

Mode of Inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Sources
  • Expert Review Green
  • Literature
  • Expert Review
  • Expert list
Phenotypes
  • Wilms tumor, MONDO:0006058
  • Wilms tumor predisposition, no MIM#
OMIM
609366
Clinvar variants
Variants in CTR9
Penetrance
None
Publications
Panels with this gene

History Filter Activity

9 Oct 2024, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: ctr9 has been classified as Green List (High Evidence).

9 Oct 2024, Gel status: 3

Set publications

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Publications for gene: CTR9 were set to PMID: 25099282, 39293508, 29292210

26 Sep 2024, Gel status: 3

Entity classified by Genomics England curator

Chirag Patel (Genetic Health Queensland)

Gene: ctr9 has been classified as Green List (High Evidence).

26 Sep 2024, Gel status: 1

Created, Added New Source, Set mode of inheritance, Set publications, Set Phenotypes

Chirag Patel (Genetic Health Queensland)

gene: CTR9 was added gene: CTR9 was added to Wilms Tumour. Sources: Expert list,Expert Review,Literature Mode of inheritance for gene: CTR9 was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted Publications for gene: CTR9 were set to PMID: 25099282, 39293508, 29292210 Phenotypes for gene: CTR9 were set to Wilms tumor, MONDO:0006058; Wilms tumor predisposition, no MIM# Review for gene: CTR9 was set to GREEN